Department of Medicine, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI.
Department of Medicine, Hematology/Oncology, University of Rochester Medical Center, Rochester, NY.
Clin Genitourin Cancer. 2020 Aug;18(4):e478-e483. doi: 10.1016/j.clgc.2020.01.003. Epub 2020 Jan 27.
Systemic therapy is the mainstay of treatment for metastatic urothelial carcinoma (UC). Responses to first-line platinum-based therapy tend to be short-lived with potential toxicity. Despite the approval of checkpoint inhibitors, the long-term prognosis for patients with metastatic UC remains dismal. Herein we report the case of a patient with a solitary pulmonary metastatic lesion of urothelial origin as the only site of metastatic disease who remained free of disease for more than 2 years without systemic therapy after metastasectomy. We review the literature discussing the role of combined surgical and medical management of oligometastatic UC. As our case illustrates, a growing body of evidence suggests a potential role for a multimodal approach in patients with oligometastatic UC.
系统治疗是转移性尿路上皮癌（UC）的主要治疗方法。一线铂类治疗的反应往往是短暂的，且具有潜在的毒性。尽管检查点抑制剂已获得批准，但转移性 UC 患者的长期预后仍然不佳。在此，我们报告了一例孤立性肺转移性尿路上皮起源病变的患者，该患者为转移性疾病的唯一部位，在转移瘤切除术后超过 2 年未接受全身治疗而无疾病进展。我们回顾了文献，讨论了寡转移性 UC 的联合手术和内科治疗的作用。正如我们的病例所示，越来越多的证据表明，寡转移性 UC 患者的多模式治疗可能具有潜在作用。
